Clinical Trials Browser

Withdrawn × INDUSTRY × pembrolizumab × Clear all

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2 Withdrawn

CRC

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT06395090 2025-04-08

MK-9999-01B

Phase 1/2 Withdrawn

Neoplasm Metastasis

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Phase 2 Withdrawn

Advanced Endometrial Cancer

NCT05338580 2024-04-15

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Phase 2 Withdrawn

DermatologicGenitourinaryThoracic

First-line Non-small-cell Lung Cancer

NCT05705466 2024-03-22

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04555603 2023-11-21

Axitinib Therapy Management Study

Carcinoma, Renal Cell

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05220748 2023-04-19

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Phase 1 Withdrawn

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Skin Neoplasms

NCT05234606 2022-04-12

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Phase 1/2 Withdrawn

BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04408898 2021-11-16

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT04995094 2021-11-05

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

Phase 2 Withdrawn

Melanoma

NCT03773744 2021-04-06

Pelican

Phase 1 Withdrawn

Melanoma

NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Phase 1/2 Withdrawn

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT03881111 2020-02-11

KEYNOTE-590

Phase 3 Withdrawn

Gastrointestinal

Esophageal Neoplasms

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2 Withdrawn

Neoplasms, Sarcoma, Synovial

NCT03221634 2019-03-25

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Phase 2 Withdrawn

Multiple Myeloma